PS-341 in Treating Women With Metastatic Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the breast
• * Metastatic disease
• At least 1 unidimensionally measurable lesion
• * At least 20 mm by conventional techniques OR
• * At least 10 mm by spiral CT scan
• Previously treated with 1 prior chemotherapy regimen (with or without trastuzumab \[Herceptin\]) for metastatic disease
• * Relapse during or within 6 months after completion of adjuvant chemotherapy considered treatment failure
• No known brain metastases
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Sex:
• Female
• Menopausal status:
• Not specified
• Performance status:
• ECOG 0-2
• Life expectancy:
• More than 3 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute neutrophil count greater than 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin normal
• SGOT/SGPT no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine normal OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other:
• No uncontrolled concurrent illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to bortezomib
• No other prior malignancy within the past 5 years unless curatively treated and disease free
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy:
• Prior hormonal therapy for metastatic disease allowed
• At least 4 weeks since prior hormonal therapy and recovered
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• Surgery:
• Not specified
• Other:
• Prior adjuvant therapy allowed
• At least 4 weeks since prior investigational drugs and recovered
• No other concurrent investigational or commercial agents or therapies for breast cancer
• No concurrent combination antiretroviral therapy for HIV